Radiopharm Theranostics Limited Sponsored ADR RADX 深 滬
交易中 01-28 11:13:34 美东时间
4.945
+0.025
+0.51%
華盛通- 最 高5.0899
- 今 開4.91
- 成交量 1.06万股
- 最 低 4.89
- 昨 收 4.92
- 總市值 3898.24万
- 52周最高 16.25
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 3.4962
- 委 比 -97.18%
- 總股本 788.32万
- 歷史最高 50.82
- 量 比 2.22
- 振 幅 4.06%
- 歷史最低 3.4962
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Radiopharm Theranostics Says Cash And Cash Equivalents Of Approximately $34.52m For Or The 6 Months Ended December 31, 2025 Provide Runway Into 2027
Program and Business Updates18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18RAD 101 is being evaluated in a single-arm U.S. Phase 2b clinical trial for the diagnostic performance of
01-28 20:09
Radiopharm Theranostics Raises Radiopharm Ventures Stake From 75% To 87.5% With Lead B7H3 Candidate Betabart Advancing Toward First Patient Dosing In Q1 2026
Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance
01-12 20:07
RAD Increases Ownership in Radiopharm Ventures to 87.5%
Radiopharm Ventures LLC, a joint venture between the University of Texas MD Anderson Cancer Center and Radiopharm Theranostics, was established in 2022. The company's lead candidate, Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase 1 therapeutic trial in multiple solid tumors, with the first patient expected to be dosed in Q1 2026. This marks the first global clinical trial targeting B7H3 with a systemic ...
01-12 12:00
Radiopharm Theranostics Announces Proposed Share Placement
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
2025-12-18 12:12
Radiopharm Theranostics Addresses ASX Listing Rule Compliance Issue
Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Ra...
2025-12-18 11:32
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Why Is Radiopharm Theranostics Stock Rallying Over 140%?
Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.
2025-12-16 00:59
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
2025-12-15 20:26
Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With MRI
The interim analysis showed that 92% (11/12) of the patients treated with RAD 101 achieved concordance with MRI (the primary endpoint) as assessed by PET imaging of brain metastases. The results showed significant and
2025-12-15 20:04
Radiopharm Theranostics Announces Change in Substantial Holder Status
An update from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. ...
2025-12-10 09:07
